The Math of Changing Your Mind: A Leader’s Guide to Bayesian Thinking

Beyond the Crush-Resistant Pill: Engineering the Next Generation of Anti-Abuse Drug Delivery

The Replicator Fallacy: Why Silicon Valley’s Star Trek Utopia Is Not a Universal Dream

The Subcutaneous Revolution: Hyaluronidase and the Future of Antibody Therapeutics

The 60-Second Revolution in Drug Delivery: How Effervescent Microneedles Solve the Patient Compliance Dilemma

The Deliverome Project: Revolutionizing Drug Delivery in Precision Medicine

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Standard treatment for tendon injuries often means injections that wear off quickly or drugs that go through your entire body, causing side effects. What if we could place a tiny "drug depot" right at the injury site that lasts for weeks? 🏥 Our team at the Wyss Institute has developed a new tough composite hydrogel that does exactly that. By harnessing the power of clay nanoparticl

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Executive Summary Therapeutic angiogenesis offers a powerful pathway for treating ischemic conditions, yet its clinical translation has been consistently hindered by a major biological hurdle: age-related impairment of tissue regeneration. Traditional single-growth factor therapies often struggle in senescent microenvironments because the body clears the therapeutic signals before t

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Breaking down cancer cells to build a better vaccine? 🧫🧬 We previously found a clever way to improve personalized cancer immunotherapies. Traditionally, scientists use "tumor lysate" (broken down cancer cells) to teach the immune system what to fight. The problem? Lysate doesn't always trigger a strong immune response. Enter "Reduced Cancer Cells" (RCCs). In this study, we mechani

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies An animation to accompany our "Modular biomaterials vaccine technology protects against multiple pathogens and septic shock" paper, where we describe the development of ciVAX (Composite Infection Vaccine), a modular, injectable biomaterial scaffold designed to provide broad-spectrum protection against lethal bacterial infections and sepsis. Full report @ https://is.gd/CzSnuk #sepsis

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Our "Modular biomaterials vaccine technology protects against multiple pathogens and septic shock" paper describes the development of ciVAX (Composite Infection Vaccine), a modular, injectable biomaterial scaffold designed to provide broad-spectrum protection against lethal bacterial infections and sepsis. Full report @ https://is.gd/CzSnuk #sepsis #vaccines #Biomaterials #medtech #

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Our recently published article entitled "Kinetics of De Novo Bone and Bone Marrow Niche Formation With Hybrid Click Cryogels", explores strategies to rebuild the bone marrow environment to improve the success of hematopoietic stem cell transplantation (HSCT). Full report @ https://is.gd/1tleYm Main Objective The study addresses the problem of damaged bone marrow niches following irr